Citations (38)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Nehad M Ayoub, Mona Fares, Raya Marji, Samir M Al Bashir & Rami J Yaghan. (2021) Programmed Death-Ligand 1 Expression in Breast Cancer Patients: Clinicopathological Associations from a Single-Institution Study. Breast Cancer: Targets and Therapy 13, pages 603-615.
Read now
Read now
Steven J Greco. (2019) Breast cancer risk in a rapidly aging population: advances and approaches to study the aging tissue microenvironment. Breast Cancer: Targets and Therapy 11, pages 111-113.
Read now
Read now
Articles from other publishers (36)
Md Abdus Subhan. 2023.
Flora Doffe, Layla Fuoco, Judith Michels, Sandra Jernström, Raphael Tomasi & Pierre Savagner. (2022) Evaluating immune response in vitro in a relevant microenvironment: a high-throughput microfluidic model for clinical screening. Exploration of Targeted Anti-tumor Therapy, pages 853-865.
Crossref
Crossref
Regina Padmanabhan, Hadeel Kheraldine, Ishita Gupta, Nader Meskin, Anas Hamad, Semir Vranic & Ala-Eddin Al Moustafa. (2022) Quantification of the growth suppression of HER2+ breast cancer colonies under the effect of trastuzumab and PD-1/PD-L1 inhibitor. Frontiers in Oncology 12.
Crossref
Crossref
Fatemeh Davodabadi, Mohammad Sarhadi, Javad Arabpour, Saman Sargazi, Abbas Rahdar & Ana M. Díez-Pascual. (2022) Breast cancer vaccines: New insights into immunomodulatory and nano-therapeutic approaches. Journal of Controlled Release 349, pages 844-875.
Crossref
Crossref
Raghuram Reddy, Joel Mintz, Roei Golan, Fakiha Firdaus, Roxana Ponce, Derek Van Booven, Aysswarya Manoharan, Isabelle Issa, Bonnie B. Blomberg & Himanshu Arora. (2022) Antibody Diversity in Cancer: Translational Implications and Beyond. Vaccines 10:8, pages 1165.
Crossref
Crossref
Angelica Ferrando-Díez, Eudald Felip, Anna Pous, Milana Bergamino Sirven & Mireia Margelí. (2022) Targeted Therapeutic Options and Future Perspectives for HER2-Positive Breast Cancer. Cancers 14:14, pages 3305.
Crossref
Crossref
Santiago Moragon, Cristina Hernando, Maria Teresa Martinez-Martinez, Marta Tapia, Belen Ortega-Morillo, Ana Lluch, Begoña Bermejo & Juan Miguel Cejalvo. (2022) Immunological Landscape of HER-2 Positive Breast Cancer. Cancers 14:13, pages 3167.
Crossref
Crossref
Lianru Zhang, Xipeng Zhou, Huizi Sha, Li Xie & Baorui Liu. (2022) Recent Progress on Therapeutic Vaccines for Breast Cancer. Frontiers in Oncology 12.
Crossref
Crossref
Luccas Lavareze, João Figueira Scarini, Reydson Alcides de Lima-Souza, Carolina Emerick, Raísa Sales de Sá, Iara Gonçalves Aquino, Patricia Maria Fernandes, Mayara Trevizol Gonçalves, My N. Helms, Albina Altemani, Erika Said Abu Egal & Fernanda Viviane Mariano. (2022) Salivary gland cancer in the setting of tumor microenvironment: Translational routes for therapy. Critical Reviews in Oncology/Hematology 171, pages 103605.
Crossref
Crossref
I. V. Vasilevskaya & O. E. Molchanov. (2022) IMMUNOLOGICAL FEATURES OF BREAST CANCER. Laboratornaya i klinicheskaya meditsina. Farmatsiya:5, pages 27-36.
Crossref
Crossref
Anastasios Kyriazoglou, Maria Kaparelou, Georgios Goumas, Michael Liontos, Roubini Zakopoulou, Eleni Zografos, Anna Zygogianni, Meletios Athanasios Dimopoulos & Flora Zagouri. (2022) Immunotherapy in HER2-Positive Breast Cancer: A Systematic Review. Breast Care 17:1, pages 63-70.
Crossref
Crossref
Alexis Catala, Monika Dzieciatkowska, Guankui Wang, Arthur Gutierrez-Hartmann, Dmitri Simberg, Kirk C. Hansen, Angelo D’Alessandro & Carlos E. Catalano. (2021) Targeted Intracellular Delivery of Trastuzumab Using Designer Phage Lambda Nanoparticles Alters Cellular Programs in Human Breast Cancer Cells. ACS Nano 15:7, pages 11789-11805.
Crossref
Crossref
He Hu & Nicole F. Steinmetz. (2021) Development of a Virus-Like Particle-Based Anti-HER2 Breast Cancer Vaccine. Cancers 13:12, pages 2909.
Crossref
Crossref
Miganoosh Simonian, Mozhan Haji Ghaffari & Babak Negahdari. (2021) Immunotherapy for Breast Cancer Treatment. Iranian Biomedical Journal 25:3, pages 140-156.
Crossref
Crossref
Himgauri Naik, Jafrin Jobayer Sonju, Sitanshu Singh, Ioulia Chatzistamou, Leeza Shrestha, Ted Gauthier & Seetharama Jois. (2021) Lipidated Peptidomimetic Ligand-Functionalized HER2 Targeted Liposome as Nano-Carrier Designed for Doxorubicin Delivery in Cancer Therapy. Pharmaceuticals 14:3, pages 221.
Crossref
Crossref
Wende Li, Sen Li, Ivy X. Chen, Yujiao Liu, Rakesh R. Ramjiawan, Chi-Ho Leung, Leo E. Gerweck, Dai Fukumura, Jay S. Loeffler, Rakesh K. Jain, Dan G. Duda & Peigen Huang. (2021) Combining losartan with radiotherapy increases tumor control and inhibits lung metastases from a HER2/neu-positive orthotopic breast cancer model. Radiation Oncology 16:1.
Crossref
Crossref
Clare C Yu, Juliana C Wortman, Ting-Fang He, Shawn Solomon, Robert Z Zhang, Anthony Rosario, Roger Wang, Travis Y Tu, Daniel Schmolze, Yuan Yuan, Susan E Yost, Xuefei Li, Herbert Levine, Gurinder Atwal & Peter P Lee. (2021) Physics approaches to the spatial distribution of immune cells in tumors. Reports on Progress in Physics 84:2, pages 022601.
Crossref
Crossref
Tang Hexiao, Bai Yuquan, Xiong Lecai, Wei Yanhong, Shen Li, Hu Weidong, Xu Ming, Zhou Xuefeng, Pan Gaofeng, Zhang Li, Zhu Minglin, Tang Zheng, Yang Zetian, Zhou Xiao, Cai Yi, Michael Lanuti & Zhao Jinping. (2021) Knockdown of CENPF inhibits the progression of lung adenocarcinoma mediated by ERβ2/5 pathway. Aging 13:2, pages 2604-2625.
Crossref
Crossref
Sandeep Pallerla, Ata ur Rahman Mohammed Abdul, Jill Comeau & Seetharama Jois. (2021) Cancer Vaccines, Treatment of the Future: With Emphasis on HER2-Positive Breast Cancer. International Journal of Molecular Sciences 22:2, pages 779.
Crossref
Crossref
Mona Kamal Saadeldin, Amal Kamal Abdel-Aziz & Ahmed Abdellatif. (2021) Dendritic cell vaccine immunotherapy; the beginning of the end of cancer and COVID-19. A hypothesis. Medical Hypotheses 146, pages 110365.
Crossref
Crossref
Peipei Wang, Yang Fu, Yueyun Chen, Qing Li, Ye Hong, Ting Liu & Zhenyu Ding. (2020) Nomogram Personalizes and Visualizes the Overall Survival of Patients with Triple-Negative Breast Cancer Based on the Immune Genome. BioMed Research International 2020, pages 1-16.
Crossref
Crossref
Shigao Huang & Qi Zhao. (2020) Nanomedicine-Combined Immunotherapy for Cancer. Current Medicinal Chemistry 27:34, pages 5716-5729.
Crossref
Crossref
Vikas Jain, Hitesh Kumar, Haritha V. Anod, Pallavi Chand, N. Vishal Gupta, Surajit Dey & Siddharth S. Kesharwani. (2020) A review of nanotechnology-based approaches for breast cancer and triple-negative breast cancer. Journal of Controlled Release 326, pages 628-647.
Crossref
Crossref
Aena Patel, Nisha Unni & Yan Peng. (2020) The Changing Paradigm for the Treatment of HER2-Positive Breast Cancer. Cancers 12:8, pages 2081.
Crossref
Crossref
Reem Saleh, Salman M. Toor, Dana Al-Ali, Varun Sasidharan Nair & Eyad Elkord. (2020) Blockade of PD-1, PD-L1, and TIM-3 Altered Distinct Immune- and Cancer-Related Signaling Pathways in the Transcriptome of Human Breast Cancer Explants. Genes 11:6, pages 703.
Crossref
Crossref
Robert Power, Maeve A. Lowery, John V. Reynolds & Margaret R. Dunne. (2020) The Cancer-Immune Set Point in Oesophageal Cancer. Frontiers in Oncology 10.
Crossref
Crossref
Joshua Tobias, Claire Battin, Annika De Sousa Linhares, Michael Lebens, Karin Baier, Katharina Ambroz, Mirjana Drinić, Sandra Högler, Aleksandra Inic-Kanada, Erika Garner-Spitzer, Matthias Preusser, Lukas Kenner, Michael Kundi, Christoph C. Zielinski, Peter Steinberger & Ursula Wiedermann. (2020) A New Strategy Toward B Cell-Based Cancer Vaccines by Active Immunization With Mimotopes of Immune Checkpoint Inhibitors. Frontiers in Immunology 11.
Crossref
Crossref
Robert D. Carlson, John C. FlickingerJr.Jr. & Adam E. Snook. (2020) Talkin’ Toxins: From Coley’s to Modern Cancer Immunotherapy. Toxins 12:4, pages 241.
Crossref
Crossref
Regina Padmanabhan, Hadeel Shafeeq Kheraldine, Nader Meskin, Semir Vranic & Ala-Eddin Al Moustafa. (2020) Crosstalk between HER2 and PD-1/PD-L1 in Breast Cancer: From Clinical Applications to Mathematical Models. Cancers 12:3, pages 636.
Crossref
Crossref
Sara Verdura, Elisabet Cuyàs, Eric Cortada, Joan Brunet, Eugeni Lopez-Bonet, Begoña Martin-Castillo, Joaquim Bosch-Barrera, José Antonio Encinar & Javier A. Menendez. (2020) Resveratrol targets PD-L1 glycosylation and dimerization to enhance antitumor T-cell immunity. Aging 12:1, pages 8-34.
Crossref
Crossref
Jesús Soberino, Fabricio Racca, José Pérez-García, Luis F. García-Fernández & Javier Cortés. (2019) Immunotherapy for HER2-Positive Breast Cancer: Changing the Paradigm. Current Breast Cancer Reports 11:4, pages 248-258.
Crossref
Crossref
Tala M. Abu Samaan, Marek Samec, Alena Liskova, Peter Kubatka & Dietrich Büsselberg. (2019) Paclitaxel’s Mechanistic and Clinical Effects on Breast Cancer. Biomolecules 9:12, pages 789.
Crossref
Crossref
Priyanka Tharkar, Ramya Varanasi, Wu Shun Felix Wong, Craig T. Jin & Wojciech Chrzanowski. (2019) Nano-Enhanced Drug Delivery and Therapeutic Ultrasound for Cancer Treatment and Beyond. Frontiers in Bioengineering and Biotechnology 7.
Crossref
Crossref
Marilina García-Aranda & Maximino Redondo. (2019) Immunotherapy: A Challenge of Breast Cancer Treatment. Cancers 11:12, pages 1822.
Crossref
Crossref
Tower, Ruppert & Britt. (2019) The Immune Microenvironment of Breast Cancer Progression. Cancers 11:9, pages 1375.
Crossref
Crossref
Bin Wang, Huayong Jiang, Tingyang Zhou, Ning Ma, Wei Liu, Yajie Wang & Li Zuo. (2019) Expression of ICOSL is associated with decreased survival in invasive breast cancer. PeerJ 7, pages e6903.
Crossref
Crossref